PMID- 8615321
OWN - NLM
STAT- MEDLINE
DCOM- 19960605
LR  - 20190626
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 131
IP  - 5
DP  - 1996 May
TI  - Enhanced sensitivity of the failing human myocardium to cardiac glycosides and 
      Na(+)-channel activators.
PG  - 988-93
AB  - Cardiac glycosides and Na+ -channel activators increase intracellular Na+ and 
      thereby enhance the transport rate of the sarcolemmal Na+/Ca2+ exchanger. We 
      tested the hypothesis of whether increased expression of the Na+/Ca2+ exchanger 
      in failing human myocardium is accompanied by enhanced sensitivity of the failing 
      human myocardium toward cardiac glycosides and Na+ -channel activators. We 
      studied the positive inotropic effects of the new Na+ -channel activator BDF and 
      the cardiac glycoside ouabain in human failing (New York Heart Association [NYHA] 
      functional class IV, heart transplants for dilated cardiomyopathy, n = 11) and 
      nonfailing (donor hearts, n = 5) myocardium on electrically driven left 
      ventricular papillary muscle strips (1 Hz, 37 degrees C). The effectiveness of 
      ouabain and BDF to increase force of contraction was similar in human nonfailing 
      and failing myocardium. BDF was more potent to increase force of contraction in 
      failing than in nonfailing tissue (p < 0.05). The time until maximal inotropic 
      effect developed after ouabain was significantly shorter in NYHA IV (mean 150 +/- 
      16 min) than in nonfailing myocardium (mean 240 +/- 20 min). These results 
      suggest that human failing myocardium exerts and enhanced sensitivity to cardiac 
      glycosides and Na+ -channel activators, possibly because of enhanced expression 
      of the Na+/Ca2+ exchanger or because of an altered intracellular Na+ 
      -homeostasis.
FAU - Schwinger, R H
AU  - Schwinger RH
AD  - Medizinische Klinik III, Universitat zu Koln, Germany.
FAU - Muller-Ehmsen, J
AU  - Muller-Ehmsen J
FAU - Frank, K
AU  - Frank K
FAU - Koch, A
AU  - Koch A
FAU - Erdmann, E
AU  - Erdmann E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Calcium Channels)
RN  - 0 (Cardiac Glycosides)
RN  - 0 (Sodium Channels)
RN  - 5ACL011P69 (Ouabain)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Calcium Channels/drug effects
MH  - Cardiac Glycosides/*pharmacology
MH  - Cardiomyopathy, Dilated/*pathology/physiopathology
MH  - Female
MH  - Heart/*drug effects
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Middle Aged
MH  - Myocardium/pathology
MH  - Ouabain/pharmacology
MH  - Papillary Muscles/pathology/physiopathology
MH  - Sodium Channels/*drug effects
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
AID - S0002-8703(96)90184-2 [pii]
AID - 10.1016/s0002-8703(96)90184-2 [doi]
PST - ppublish
SO  - Am Heart J. 1996 May;131(5):988-93. doi: 10.1016/s0002-8703(96)90184-2.